Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Symbicort Turbuhaler vs Standard Treatment in Japanese COPD Patients
NCT01070784Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Jan 2010
- Primary completion
- Oct 2011
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of budesonide in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by AstraZeneca. Primary endpoints: Clinical Laboratory Test: Haematology at 52 weeks, Clinical Laboratory Test: Clinical Chemistry at 52 weeks and 2 more. Started Jan 2010; status: completed.
02
Drugs
budesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT01070784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01070784.